Pavblu, an Eylea biosimilar, shows stable vision outcomes and minimal side effects in real-world use, promising a reliable ...

The authors of an opinion piece in The Lancet Psychiatry make a case for paying more attention to the autistic features of ...

International audience surveys from last year’s menopause documentary, The (M) Factor, shed light on the ongoing need for ...

Veena Joy, the U.S. autoimmunity lead for medical and scientific affairs at Thermo Fisher Scientific, discusses the latest in ...

Farxiga, along with insulin and monitoring for diabetic ketoacidosis, shows promise for kidney and glucose control in youth with Type 1 diabetes.

An expert discusses how clinics can successfully implement gene therapy workflows by establishing strong institutional protocols, assigning dedicated clinic coordinators, and using strategies like ...

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the ...

Step therapy by Medicare Advantage plans was also associated with more injections, although that result fell short of meeting ...

Two presentations discussed the significant care disruptions when there are copay assistance shortages, with patients ...

An extension of a pivotal phase 3 trial shows that the functional and anatomic benefits of Eylea HD (aflibercept 8 milligram dose) have staying power in people with neovascular (wet) age-related ...

A new analysis finds that prior authorization for anti-VEGF therapies increases societal costs despite minimal insurer savings, burdening patients, workplaces, and providers.

Homecare Homebase revealed over 4 million patients are denied home health services annually, highlighting critical access issues and the impact of proposed Medicare cuts.